Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 10
Submit an article Journal homepage
442
Views
49
CrossRef citations to date
0
Altmetric
Reviews

Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease

Rosanne M Séguin Topigen Pharmaceuticals, Inc., Immunology and Development Support, 2901 Rachel East Street, Suite 13, Montréal, Québec, H1W 4A4, Canada +514 868 0077; +514 868 0011; [email protected]
&
Nicolay Ferrari Topigen Pharmaceuticals, Inc., Immunology and Development Support, 2901 Rachel East Street, Suite 13, Montréal, Québec, H1W 4A4, Canada +514 868 0077; +514 868 0011; [email protected]
Pages 1505-1517 | Published online: 28 Aug 2009

Bibliography

  • Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75(1):280-4
  • Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
  • Lima WF, Crooke ST. Highly efficient endonucleolytic cleavage of RNA by a Cys2His2 zinc-finger peptide. Proc Natl Acad Sci USA 1999;96(18):10010-5
  • Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27(1):91-105
  • Krieg A, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev 1996;6(2):133-9
  • Krieg AM, Yi A-K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374(6522):546-9
  • Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45(9):1628-50
  • Mann M, Dzau V. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000;106(9):1071-5
  • Masoli M, Beasley R. Asthma exacerbations and inhaled corticosteroids. Lancet 2004;363(9416):1236
  • Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS task force on difficult/therapy-resistant asthma. European Respiratory Society. Eur Respir J 1999;13(5):1198-208
  • Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40-7
  • Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007;29(1):56-62
  • Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-16
  • Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):506-12
  • Murray CJL, Lopez AD, Mathers CD, Stein CA. The global burden of disease 2000 project; aims, methods, and data sources. In: Organisation WH, editor, Global programme on evidence for health policy discussion paper. Geneva [governmental document] 2001. p. 1-57
  • Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-9
  • Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1(8222):681-6
  • Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-8
  • Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365(9454):167-75
  • Templin M, Levin A, Graham M, et al. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev 2000;10(5):359-68
  • Ali S, Leonard SA, Kukoly CA, et al. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med 2001;163(4):989-93
  • Moschos SA, Spinks K, Williams AE, Lindsay MA. Targeting the lung using siRNA and antisense based oligonucleotides. Curr Pharm Des 2008;14(34):3620-7
  • Jason TLH, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004;201(1):66-83
  • Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem 2003;270(8):1628-44
  • Crooke ST, editor, Antisense drug technology: principles, strategies and applications. 2nd edition. Boca Raton FL: CRC Press 2008.
  • Ghosh C, Iversen PL. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Development 2000;10(4):263-74
  • Popplewell LJ, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 2009;17(3):554-61
  • Aartsma-Rus A, van Ommen G-JB. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007;13(10):1609-24
  • Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7(9):759-70
  • Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 1993;148(1):91-7
  • Polosa R, Holgate ST. Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. Curr Drug Targets 2006;7(6):699-706
  • Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997;385(6618):721-5
  • Ball HA, Van Scott MR, Robinson CB. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy Immunol 2004;27(3):207-17
  • Ball H, Sandrasagra A, Tang L, et al. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics 2003;3:97-106
  • Wilson CN. Adenosine receptors and asthma in humans. Br J Pharmacol 2008;155(4):475-86
  • Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-93
  • Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84
  • Hanania NA. Targeting airway inflammation in asthma. Chest 2008;133(4):989-98
  • Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159(9):4593-601
  • Allakhverdi Z, Allam M, Guimond A, et al. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann NY Acad Sci 2006;1082:62-73
  • Allakhverdi Z, Lamkhioued B, Olivenstein R, et al. CD8 depletion-induced late airway response is characterized by eosinophilia, increased eotaxin, and decreased IFN-gamma expression in rats. Am J Respir Crit Care Med 2000;162(3):1123-31
  • Fortin M, Ferrari N, Higgins M-E, et al. Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. Oligonucleotides 2006;16:203-12
  • Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol 2006;533(1-3):77-88
  • Multiple dose ASM8 in mild asthmatics. September 11, 2007; cited 13 April 2009. Available from: http://clincialtrials.gov/ ct2/show/NCT00402948
  • Study to evaluate the safety and efficacy of TPI ASM8 in subjects with asthma. 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00550797
  • Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008;177:952-8
  • Efficacy and safety of four escalating dose regimens of TPI ASM8 in patients with allergic asthma. January 14 2009 cited April 13 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00822861
  • Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17(1):701-38
  • Karras JG, Crosby JR, Guha M, et al. Anti-inflammatory activity of inhaled IL-4 receptor-{alpha} antisense oligonucleotide in mice. Am J Respir Cell Mol 2007;36:276-85
  • Hodges MR, Castelloe E, Chen A, et al. Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4Ralpha oligonucleotide, in healthy volunteers. In: Medicine AJoRCC, editor, American Thoracic Society, San Diego; 2009. p. A3640
  • Medina-Tato D, Watson M, Ward S. Leukocyte navigation mechanisms as targets in airway diseases. Drug Discov Today 2006;11(19-20):866-79
  • Lofthouse S, Crosby J, Tung D, et al. Aerosol delivery of VLA-4 specific antisense oligonucleotides inhibit airway inflammation and hyperresponsiveness in mice. Respirology 2005;10(Suppl 1):A11
  • Fortin M, Higgins M, Aubé P, et al. TPI 1100: an inhaled antisense oligonucleotide (AON) against phosphodiesterase (PDE) 4 and 7 with significant anti-inflammatory effects in a mouse model for COPD. [Abstract A653] Am J Respir Crit Care Med 2008;177
  • Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172(7):848-53
  • Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 2007;4(3):283-8
  • Fonseca D, Kline J. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev 2009;61(3):256-62
  • Kline JN, Waldschmidt TJ, Businga TR, et al. Cutting edge: modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160(6):2555-9
  • Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20(1):709-60
  • Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471-84
  • Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161(12):7054-62
  • Fanucchi MV, Schelegle ES, Baker GL, et al. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med 2004;170(11):1153-7
  • Gauvreau GM, Hessel EM, Boulet L-P, et al. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174(1):15-20
  • Storni T, Ruedl C, Schwarz K, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004;172(3):1777-85
  • Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39(4):562-70
  • Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from Phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases. January 13, 2009 cited 13 April 2009. Available from: http://www.cytos.com/userfiles/file/ Cytos_Press_E_090113.pdf
  • Yu D, Zhao Q, Kandimalla ER, Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett 2000;10(23):2585-8
  • Yu D, Kandimalla ER, Bhagat L, et al. ‘Immunomers’–novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002;30(20):4460-9
  • Agrawal DK, Edwan J, Kandimalla ER, et al. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol 2004;4(1):127-38
  • Zhu FG, Kandimalla ER, Yu D, et al. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol 2004;4(7):851-62
  • Dubois G, Simmons J, Martin E, et al. Effects of a novel synthetic TLR9 agonist on repeated allergen challenge in allergic monkeys. Recent Advances in Pattern Recognition Toll 2008. [Abstract p18]
  • Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101(1):25-33
  • de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6(6):443-53
  • Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003;100(17):9779-84
  • Stenton GR, Kim M-K, Nohara O, et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol 2000;164(7):3790-7
  • Stenton GR, Ulanova M, Dery RE, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169(2):1028-36
  • Ulanova M, Puttagunta L, Marcet-Palacios M, et al. Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288(3):L497-507
  • Ulanova M, Asfaha S, Stenton G, et al. Involvement of Syk protein tyrosine kinase in LPS-induced responses in macrophages. J Endotoxin Res 2007;13(2):117-25
  • ZaBeCor's investigational new drug application approved by the FDA. November 12, 2008 cited 13 April 2009. Available from: http://www.zabecor.com/news/news030409.php
  • Quarcoo D, Weixer S, Groneberg, D,et al. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol 2004;114(2):288-95
  • Kerstjens HA, Oosterhuis B, van Marle SP et al. Single dose decoy oligonucleotide directed against STAT-1 attenuates bronchial hyperresponsiveness to AMP. Proc Am Thorac Soc 2006;3:A825 [abstract]
  • AVONTEC announce results of a multiple dose clinical proof of concept study with its drug candidate AVT-01 decoy ODN in asthmatic patients. February 28, 2008 cited 13 April 2009. Available from: http://avontec.com/pdf/PR_asthma_phase_IIa_2008_02_28.pdf
  • Ferrari N, Bergeron D, Tedeschi A-L, et al. Characterization of antisense oligonucleotides comprising 2′-Deoxy-2′-Fluoro-beta-D-Arabinonucleic Acid (FANA): specificity, potency, and duration of activity. Ann NY Acad Sci 2006;1082:91-102
  • McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 1999;274(3):1715-22
  • Sternberger M, Schmiedeknecht A, Kretschmer A, et al. Geneblocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense Nucleic Acid Drug Dev 2002;12(3):131-43
  • Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. PNAS 2000;97(10):5633-8
  • Yoo BH, Bochkareva E, Bochkarev A, et al. 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res 2004;32(6):2008-16
  • Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18(4):305-20
  • Geary R, Yu R, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-{alpha} phosphorothioate 2′-o-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003;31(11):1419-28
  • Guimond A, Viau E, Aube P, et al. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008;21(2):845-54
  • Duan W, Chan JH, McKay K, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005;171(6):571-8
  • Griesenbach U, Kitson C, Escudero Garcia S, et al. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res 2006;7:26-41
  • Zhang X, Shan P, Jiang D, et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004;279(11):10677-84
  • Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36(12):4158-71
  • Popescu F-D. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005;9(4):840-53

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.